Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,030 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allogeneic Stem-Cell Transplant Clear all
Terminated Phase 2 Interventional Results available

Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

NCT00075023
View directory record Official record
Conditions
Graft-versus-Host Disease, Stomatitis
Interventions
Thalidomide Gel, Placebo Gel
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 16, 2026, 5:10 AM EDT
Terminated Not applicable Interventional Results available

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 44 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 16, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant

NCT00472329
View directory record Official record
Conditions
Graft Failure
Interventions
Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
Procedure · Drug
Lead sponsor
Colorado Blood Cancer Institute
Other
Eligibility
18 Years to 74 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

NCT03680092
View directory record Official record
Conditions
GVHD, Hematologic Neoplasms
Interventions
Cyclophosphamide, abatacept, Methotrexate, Tacrolimus
Drug
Lead sponsor
Dimitrios Tzachanis, MD PhD
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 16, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT06784336
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant
Interventions
Iron chelation, Potato Resistant Starch
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

FM 140 vs FM100 Study in Patients With Multiple Myeloma

NCT00505895
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Fludarabine, Stem Cell Infusion, Rituximab
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 16, 2026, 5:10 AM EDT
Withdrawn Phase 2 Interventional

Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

NCT01047072
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
fludarabine phosphate, total-body irradiation, tacrolimus, mycophenolate mofetil, rituximab, cyclophosphamide, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Radiation · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 16, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT06093867
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Terminated Phase 1 Interventional

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02057770
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
busulfan, fludarabine phosphate, total-body irradiation (TBI), Stem cell transplant, cyclophosphamide, tocilizumab
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 16, 2026, 5:10 AM EDT
Completed No phase listed Observational

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

NCT03200977
View directory record Official record
Conditions
Lymphoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Lawrenceville, New Jersey • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

NCT01919619
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, T-Cell Non-Hodgkin Lymphoma
Interventions
Ipilimumab, Lenalidomide
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 16, 2026, 5:10 AM EDT
Withdrawn Phase 2 Interventional

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

NCT06297629
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
ASTX727, Donor Lymphocyte Infusion
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia

NCT00590460
View directory record Official record
Conditions
Fanconi Anemia, Severe Aplastic Anemia
Interventions
CAMPATH-1H, Anti-CD45, Fludarabine, Stem cell infusion
Biological · Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

NCT01203020
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Busulfan, Fludarabine
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Non-Myeloablative Allogeneic Stem Cell Transplantation

NCT00525876
View directory record Official record
Conditions
Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Rituximab, Alemtuzumab, Allogeneic Stem Cell Infusion
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 16, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

NCT04014374
View directory record Official record
Conditions
Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
Interventions
Not listed
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

NCT01982682
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer
Interventions
Total-Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide, Allogeneic hematopoietic stem cell transplantation (HSCT), Mycophenolate mofetil
Radiation · Biological · Drug + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 16, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

NCT00060424
View directory record Official record
Conditions
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Interventions
Cyclosporine, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 16, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

NCT00499889
View directory record Official record
Conditions
Leukemia
Interventions
Imatinib Mesylate, Fludarabine (Fludara), Busulfan, Antithymocyte Globulin (ATG), Tacrolimus, Methotrexate, Donor lymphocyte infusion (DLI), Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants

NCT00673868
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
CMV Specific Cytotoxic T Lymphocytes
Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

NCT02756572
View directory record Official record
Conditions
Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cladribine, Cyclosporine, Cytarabine, Filgrastim, Fludarabine Phosphate, Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan, Mitoxantrone Hydrochloride, Mycophenolate Mofetil, Questionnaire Administration, Sirolimus, Total-Body Irradiation, Melphalan Hydrochloride
Drug · Biological · Procedure + 2 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 16, 2026, 5:10 AM EDT
Completed No phase listed Observational

Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

NCT02039557
View directory record Official record
Conditions
Patients Transplanted With NiCord/CordIn (Omidubicel)
Interventions
NiCord®/CordIn™ (omidubicel)
Genetic
Lead sponsor
Gamida Cell ltd
Industry
Eligibility
2 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
5
States / cities
Oakland, California • Maywood, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 16, 2026, 5:10 AM EDT